Bloomberg – Mylan’s Pay for CEO Bresch Grates on Lawmakers, Many Investors

September 22, 2016

Mylan NV faces intense scrutiny from lawmakers after the company raised the price of its EpiPen allergy shot. Robin Ferracone, CEO of Farient Advisors, comments on CEO Heather Bresch’s Say on Pay record and how it reflects on governance.

Read on Bloomberg

© 2022 Farient Advisors LLC. | Privacy Policy | Site by: Treacle Media